LXRX: I don't get it. Why do such a complicated, unusual deal? Who benefits? And calling these investors 'private equity' is pretty odd too. The usual private equity model is to buy something that generates cash flow - borrowing most of the money for the purchase. Are these investors borrowing the money?
Hey, maybe biotech will now have a 'private equity bid'.
News 
Market Data 
Discover 
AI
